Vioxx Litigation May Freeze Class-Wide Drug Development, AEI Scholar Calfee Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Former FDA Chief Counsel Troy says Merck’s strategy to defend each case independently may backfire.
You may also be interested in...
Increased Safety Concerns Could Reduce Drug Development Pipelines By 20%, IMS Says
The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.
Increased Safety Concerns Could Reduce Drug Development Pipelines By 20%, IMS Says
The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.
Merck's Appeal In Vioxx Case Likely To Focus On Expert Testimony, Evidentiary Rulings
In the first Vioxx product liability case to reach trial, a Texas jury awards the plaintiff $253.5 mil. in damages, the bulk of which are punitive damages that would be capped under state law.